Abstract Glucagon-like peptide-1 (GLP-1) controls islet hormone secretion, gut motility, and
body weight, supporting development of GLP-1 receptor agonists (GLP-1RA) for the …

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease,
affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available …

The pathogenesis of non-alcoholic fatty liver disease, particularly the mechanisms whereby
a minority of patients develop a more severe phenotype characterised by hepatocellular …

The global prevalence of nonalcoholic fatty liver disease (NAFLD) is estimated to be 25%
and continues to rise worldwide in the setting of the obesity epidemic. This increase is …

Summary Background Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic steatosis,
concentrations of liver enzymes, and insulin resistance in murine models of fatty liver …

Aims/hypothesis Liraglutide, a daily injectable glucagon-like peptide-1 receptor (GLP-1r)
agonist, has been shown to reduce liver fat content (LFC) in humans. Data regarding the …

Incretin peptides, principally GLP-1 and GIP, regulate islet hormone secretion, glucose
concentrations, lipid metabolism, gut motility, appetite and body weight, and immune …

Background & Aims Insulin resistance and lipotoxicity are pathognomonic in non-alcoholic
steatohepatitis (NASH). Glucagon-like peptide-1 (GLP-1) analogues are licensed for type 2 …

The incretin hormone Glucagon-Like Peptide-1 (GLP-1) is best known for its “incretin effect”
in restoring glucose homeostasis in diabetics, however, it is now apparent that it has a …

Background and aims Non-alcoholic steatohepatitis (NASH), the potentially progressive
form of nonalcoholic fatty liver disease (NAFLD), is the pandemic liver disease of our time …